Le Michelle, Gabrielli Sofianne, De Schryver Sarah, Ben-Shoshan Moshe
Division of Allergy, Immunology and Dermatology, Department of Pediatrics, McGill University Health Center, Montreal, QC, Canada.
Open Access Emerg Med. 2019 Nov 1;11:249-263. doi: 10.2147/OAEM.S200342. eCollection 2019.
Idiopathic anaphylaxis (IA) is a diagnosis of exclusion and represents a major diagnostic and management challenge. There are no current guidelines for diagnosis and management of IA. We aim to present a systematic review of the literature on adult and pediatric IA.
We conducted a systematic review of original articles published in the past 22 years regarding diagnosis and management strategies of adult and pediatric IA.
The current proposed diagnostic approach and treatment regimens are based on a few small studies. Future large-scale studies are required. IA is a diagnosis of exclusion and should be made only after extensive evaluation excludes potential anaphylaxis triggers as well as non-allergic conditions with a similar presentation. There is currently no diagnostic consensus for IA. Furthermore, the current proposed treatment regimens are limited and rely on prophylactic treatment with antihistamines and prednisone for patients with frequent episodes. However, daily treatment with systemic steroids has well-recognized serious adverse effects. More recently, the use of biologics was suggested to benefit patients with IA, although the optimal management protocol is not yet established.
Future studies are needed to optimize diagnosis and treatment strategies in adult and pediatric cases of IA. Omalizumab may be a promising novel therapeutic option for adult and pediatric IA.
特发性过敏反应(IA)是一种排除性诊断,是主要的诊断和管理挑战。目前尚无IA的诊断和管理指南。我们旨在对关于成人和儿童IA的文献进行系统综述。
我们对过去22年发表的关于成人和儿童IA诊断和管理策略的原始文章进行了系统综述。
目前提出的诊断方法和治疗方案基于少数小型研究。未来需要进行大规模研究。IA是一种排除性诊断,只有在广泛评估排除潜在的过敏反应触发因素以及具有相似表现的非过敏性疾病后才能做出诊断。目前IA尚无诊断共识。此外,目前提出的治疗方案有限,对于发作频繁的患者依赖于使用抗组胺药和泼尼松进行预防性治疗。然而,全身用类固醇的每日治疗具有公认的严重不良反应。最近,有人建议使用生物制剂对IA患者有益,尽管尚未建立最佳管理方案。
需要开展进一步研究以优化成人和儿童IA病例的诊断和治疗策略。奥马珠单抗可能是成人和儿童IA一种有前景的新型治疗选择。